Teva reaffirms ‘Pivot to Growth’ strategy with launch of acceleration phase

Teva (TEVA) Pharmaceutical is hosting a 2025 Innovation & Strategy Day, to launch the acceleration phase of its “Pivot to Growth” strategy and to discuss portfolio priorities as it evolves into a global biopharmaceutical leader. The event, led by President and CEO Richard Francis and members of Teva’s executive management team, will outline the company’s strategy, progress and roadmap to deliver sustained shareholder value through 2030 and beyond. Presentations begin at 8:30 a.m. Eastern Time and are expected to conclude at 12:30 p.m. Eastern Time. A live webcast of the event and presentation materials will be available on Teva’s Investor Relations website. Teva has completed Phase 1 of the Strategy: Return to Growth, delivering: 9 consecutive quarters of growth – fueled by strong momentum from key innovative growth drivers. More than $2.3B in revenue in 2024 from Teva’s innovative portfolio: AUSTEDO, AJOVY, and UZEDY. Returning the generics business to growth with +5% in revenues across regions, and top 3 global portfolio with potential for five product launches by 2027. Teva’s innovative portfolio continues to drive strong performance and future potential. The company has announced its target to build a greater than $5B innovative medicines franchise by 2030, driven by AUSTEDO, AJOVY, UZEDY, and a robust pipeline of late-stage assets including olanzapine LAI, duvakitug, DARI, and emrusolmin. AUSTEDO: Expected to exceed $2.5B in sales by 2027 and exceed $3B by 2030. AJOVY: A globally established brand with presence across 43 countries and expected launches in 3 additional countries this year. LAI schizophrenia franchise expected to have $1.5B to $2B in peak sales UZEDY: Fastest growing LAI with greater than 60% risperidone LAI market share captured. Olanzapine LAI: Set to expand our LAI franchise – U.S. NDA filing expected in H2 2025. Teva’s late-stage pipeline includes multiple assets with proven mechanisms and blockbuster potential: duvakitug: A potentially best-in-class treatment for inflammatory bowel disease, with potential expansion into additional indications with peak sales potential of up to $2-$5B. DARI: A dual-action rescue inhaler for asthma, that could address a significant unmet need as a first ICS/SABA combination for both adult and pediatric patient populations, with peak sales potential of ~$1B. olanzapine LAI: A differentiated long-acting injectable for schizophrenia, that we expect to build on the success of UZEDY and expand Teva’s LAI franchise. emrusolmin: A potential first-in-class treatment for Multiple System Atrophy, a rare and fatal neurodegenerative disease that currently has no approved treatments, with peak sales potential of more than $2B. TEV-‘408: Anti-IL-15 antibody granted fast-track designation by the U.S. Food and Drug Administration to be evaluated for the treatment of celiac disease, with peak sales potential of more than $1B. Teva’s generics, biosimilars, and OTC business remains a stable, robust and cash-generating powerhouse. Teva continues to lead in generics globally, with a strong pipeline of complex generics and biosimilars. 13 biosimilars in the pipeline, with potential for 5 new launches planned by 2027. Strategic focus on complex generics, biosimilars, and OTC to compensate gRevlimid by 2027. Expanding on our $1.1B OTC business with a global portfolio of strong local and global brands, outperforming the market with double-digit growth. Continued manufacturing transformation to enhance competitiveness and margins.Teva is accelerating shareholder value creation with reaffirmed its 2027 financial targets: Revenue growth driven by innovative launches and stable generics business. Operating margin expansion to 30% by 2027. Free cash flow of greater than$2.7B in 2027 and greater than$3.5B by 2030. Payment of debt down to 2x net leverage. ~$700M in net savings through modernizing the organization and improving operational efficiencies, enabling reinvestment in R&D and commercial capabilities.